InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: None

Monday, 11/30/2020 4:30:00 PM

Monday, November 30, 2020 4:30:00 PM

Post# of 402567
"There has been discussion about "Low Absorption" of Brilacidin in other indications (past Clinical Trials results) the implication is that maybe more than is safe would have to be administered to get the intended result.

That is far from the truth and reflects an ignorance on the issue (or just outright deception) of sometimes the drug maker wants HIGH Absorbtion and sometimes the want LOW Absorbtion, depending on the indication being treated.

The FACT IS, with Brilacidin and Covid-19. Brilacidin treatment for Covid-19 is by IV injection. So this whole issue of "low absorption" is not relevant as Brilacidin is 100% being placed into the bloodstream. The absorption issue only has to do with topical delivery and pills. For IBD diseases such as UC trials etc, IPIX wants low absorption.

So the entire discussion, if posters are trying to sow doubt or make an issue, it is a NON-ISSUE, esp. against Covid-19.""

Go Leo & IPIX!

Brilacidin In a human lung cell line infected by SARS-CoV-2, Brilacidin achieved a high Selectivity Index rating of 426.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News